Advertisement
Screener

CYTOSORBENTS CORPORATION (CTSO) Overview

CYTOSORBENTS CORPORATION (CTSO) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -0.07; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.08; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -0.05; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual 0.03; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$0.29$0.55$1.03$1.93$3.60$6.732025-09-292026-09-29$0.29$0.58$1.13$2.22$4.35$8.532021-09-292026-09-29$0.29$0.65$1.44$3.18$7.03$15.542016-09-292026-09-29$0.29$0.88$2.64$7.91$23.67$70.882006-09-292026-09-29$0.29$0.94$3.03$9.72$31.18$100.012006-08-082026-09-29

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$4.00
Previous close
$4.02
Change
-$0.02
Change (%)
-0.50%
Close date
2026-09-29
Previous close date
2026-09-28
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

CTSO
+525.00%
S&P 500
(m)

1 year

CTSO
+330.11%
S&P 500
(m)

3 years

CTSO
+112.77%
S&P 500
(m)

5 years

CTSO
-50.62%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual -0.07

-0.16-0.070.020.120.2131 Mar 2025: estimate (m); actual -0.0231 Mar 2025(m)30 Jun 2025: estimate (m); actual 0.0330 Jun 2025(m)30 Sept 2025: estimate (m); actual -0.0530 Sept 2025(m)31 Mar 2026: estimate (m); actual -0.0831 Mar 2026(m)30 Jun 2026: estimate (m); actual -0.0730 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)-0.07(m)(m)
1 Jan 202631 Mar 2026(m)-0.08(m)(m)
1 Jul 202530 Sept 2025(m)-0.05(m)(m)
1 Apr 202530 Jun 2025(m)0.03(m)(m)
1 Jan 202531 Mar 2025(m)-0.02(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual -0.13

-0.83-0.61-0.39-0.170.0531 Dec 2021: estimate (m); actual -0.5731 Dec 2021(m)31 Dec 2022: estimate (m); actual -0.7531 Dec 2022(m)31 Dec 2023: estimate (m); actual -0.6531 Dec 2023(m)31 Dec 2024: estimate (m); actual -0.3831 Dec 2024(m)31 Dec 2025: estimate (m); actual -0.1331 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)-0.13(m)(m)
1 Jan 202431 Dec 2024(m)-0.38(m)(m)
1 Jan 202331 Dec 2023(m)-0.65(m)(m)
1 Jan 202231 Dec 2022(m)-0.75(m)(m)
1 Jan 202131 Dec 2021(m)-0.57(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 9.63M ■ Earnings -4.42M — Profit margin -45.85%

-6.63M-95.1%-0.63M-56.3%5.37M-17.5%11.38M21.2%31 Mar 2019: revenue 5.19M; earnings -4.88M; profit margin -94.07%31 Mar 201930 Jun 2019: revenue 6.23M; earnings -3.55M; profit margin -56.92%30 Jun 201930 Jun 2025: revenue 9.62M; earnings 1.95M; profit margin 20.25%30 Jun 202530 Jun 2026: revenue 9.63M; earnings -4.42M; profit margin -45.85%30 Jun 2026

31 Dec 2018 ■ Revenue 22.50M ■ Earnings -17.21M — Profit margin -76.48%

-21.98M-198.8%-5.56M-150.8%10.85M-102.8%27.27M-54.8%31 Dec 2015: revenue 4.79M; earnings -9.48M; profit margin -197.78%31 Dec 201531 Dec 2016: revenue 9.53M; earnings -11.76M; profit margin -123.46%31 Dec 201631 Dec 2017: revenue 15.15M; earnings -8.46M; profit margin -55.84%31 Dec 201731 Dec 2018: revenue 22.50M; earnings -17.21M; profit margin -76.48%31 Dec 2018

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$4.00(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$4.00High(m)Average(m)Low(m)2025-09-292026-09-29

Recent news

View more →

(m)

YouTube videos mentioning CTSO

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending (m).

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
(m)
Profit margin
(m)
Return on assets · 12 month
(m)
Stock compensation expense · all employees · 12 months
(m)
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
186.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
362.75K
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-24.81%*
Total return · month
1112.12%*
Total return · quarter
952.63%*
Total return · half year
577.97%*
Total return · year to date
525.00%*
Total return · 1 year
330.11%*
Total return · 3 years
112.77%*
Total return · 5 years
-50.62%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
(m)
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

CYTOSORBENTS CORPORATION Overview

View more →

(m)

(m)

SEC CIK
1175151
Industry (SIC)
3841 Surgical & Medical Instruments & Apparatus
Country of operation
United States
Business address
305 COLLEGE ROAD EAST, PRINCETON, New Jersey, 08540, United States
Fiscal year end
1231
Phone
973-329-8885

Similar stocks

Stock NameCountryMarket CapPE Ratio
ORASURE TECHNOLOGIES INC (OSUR)United States$0.272B-6.26
Anika Therapeutics, Inc. (ANIK)United States$0.272B-51.71
TriSalus Life Sciences, Inc. (TLSI)United States$0.283B-9.92
Mobia Medical, Inc. (MOBI)United States$0.293B
InfuSystem Holdings, Inc (INFU)United States$0.253B22.52
TREACE MEDICAL CONCEPTS, INC. (TMCI)United States$0.297B-4.32
UTAH MEDICAL PRODUCTS INC (UTMD)United States$0.238B20.93
PRO DEX INC (PDEX)United States$0.234B13.64
Embecta Corp. (EMBC)United States$0.319B2.10
Neuronetics, Inc. (STIM)United States$0.216B-3.25